These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study. Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846 [TBL] [Abstract][Full Text] [Related]
6. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Bisaga A; Comer SD; Ward AS; Popik P; Kleber HD; Fischman MW Psychopharmacology (Berl); 2001 Aug; 157(1):1-10. PubMed ID: 11512037 [TBL] [Abstract][Full Text] [Related]
7. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Bisaga A; Sullivan MA; Glass A; Mishlen K; Pavlicova M; Haney M; Raby WN; Levin FR; Carpenter KM; Mariani JJ; Nunes EV Drug Alcohol Depend; 2015 Sep; 154():38-45. PubMed ID: 26187456 [TBL] [Abstract][Full Text] [Related]
8. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence]. Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620 [TBL] [Abstract][Full Text] [Related]
9. The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal. Mannelli P; Peindl K; Wu LT; Patkar AA; Gorelick DA Am J Drug Alcohol Abuse; 2012 May; 38(3):200-5. PubMed ID: 22233189 [TBL] [Abstract][Full Text] [Related]
10. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts. Jain K; Jain R; Dhawan A J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580 [TBL] [Abstract][Full Text] [Related]
11. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Sinha R; Kimmerling A; Doebrick C; Kosten TR Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399 [TBL] [Abstract][Full Text] [Related]
12. The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats. Zakharova E; Malyshkin A; Kashkin V; Neznanova O; Sukhotina I; Danysz W; Bespalov A Behav Pharmacol; 2004 Jul; 15(4):273-8. PubMed ID: 15252277 [TBL] [Abstract][Full Text] [Related]
13. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade? Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial. Dunn KE; Tompkins DA; Bigelow GE; Strain EC JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791 [TBL] [Abstract][Full Text] [Related]
15. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Comer SD; Sullivan MA; Yu E; Rothenberg JL; Kleber HD; Kampman K; Dackis C; O'Brien CP Arch Gen Psychiatry; 2006 Feb; 63(2):210-8. PubMed ID: 16461865 [TBL] [Abstract][Full Text] [Related]
20. Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia. Harris AC; Rothwell PE; Gewirtz JC Psychopharmacology (Berl); 2008 Mar; 196(4):649-60. PubMed ID: 18026718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]